University of Parma   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Parma Italy (1332)

Organization Overview

First Clinical Trial
1994
NCT00502034
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Azienda Ospedaliera-Universitaria di Parma | Azienda Ospedaliero-Universitaria di Parma | Azienda Ospedaliero-Universitaria di Parma, Parma, Italy | Azienda Ospedaliero Universitaria di Parma, University of Parma | Azienda Unità Sanitaria Locale Reggio Emilia | Department of Food and Drugs | Department of Food and Drug, University of Parma | Department of Food Science, University of Parma | Dept. of Anesthesiology and Critical Care Medicine, University of Parma, Italy | Hospital Clinica Nova | Hospital Clínica Nova | II Unit of Anesthesia, Critical Care and Pain Medicine, University Hospital of Parma, Italy | Medical Oncology Unit - University Hospital of Parma | Parma University | Section of Anesthesiology and Critical Care, Dept. of Anesthesiology, University of Parma, Italy | Section of Anesthesiology and Critical Care, Dept. of Surgical Sciences, University of Parma | Universita degli Studi di Parma | Universitaria di Parma | University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit | University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology | University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione | University Hospitals Parma Medical Center | University of Parma | UO II Anestesia e Rianimazione, Azienda Ospedaliero-Universitaria di Parma | UO II Anestesia, Rianimazione e Terapia Antalgica, AOU Parma | UO II Anestesia, Rianimazione e Terapia Antalgica, Azienda Ospedaliero-Universitaria di Parma | UO Nefrologia, Azienda Ospedaliero-Universitaria di Parma

Active Ingredients

Drugs in Phase 4 Trials (24)

acetaminophen (tylenol) (3 trials)

atropine (2 trials)

bimatoprost (lumigan) (1 trial)

brimonidine (alphagan) (1 trial)

clonidine (catapres) (1 trial)

dorzolamide (trusopt) (1 trial)

ephedrine (1 trial)

fentanyl (Innovar) (2 trials)

furosemide (lasix) (1 trial)

ketamine (ketalar) (1 trial)

latanoprost (xalatan) (1 trial)

levobupivacaine (chirocaine) (4 trials)

lidocaine (xylocaine) (1 trial)

mepivacaine (carbocaine) (1 trial)

midazolam (versed) (1 trial)

morphine (4 trials)

oxycodone (oxycontin) (1 trial)

propofol (diprivan) (1 trial)

remifentanil (ultiva) (2 trials)

ringer's lactate (1 trial)

ropivacaine (naropin) (3 trials)

sodium chloride (1 trial)

timolol (blocadren) (1 trial)

travoprost (travatan) (1 trial)

Drugs in Phase 3 Trials (20)

aldesleukin (Proleukin) (1 trial)

bevacizumab (avastin) (1 trial)

cetuximab (erbitux) (1 trial)

empagliflozin (jardiance) (1 trial)

exenatide (byetta) (1 trial)

fluorouracil (efudex) (1 trial)

glyburide (micronase) (1 trial)

indomethacin (indocin) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

irinotecan (Camptosar) (1 trial)

levoleucovorin (fusilev) (1 trial)

metformin (glucophage) (1 trial)

methylprednisolone (medrol) (1 trial)

multivitamins (1 trial)

naltrexone (revia) (2 trials)

nivolumab (opdivo) (1 trial)

pioglitazone (actos) (1 trial)

prednisone (meticorten) (2 trials)

sitagliptin (januvia) (1 trial)

vildagliptin (1 trial)

Drugs in Phase 2 Trials (6)

colchicine (colbenemid) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

oxytocin (syntocinon) (1 trial)

tamoxifen (nolvadex) (1 trial)

tocilizumab (actemra) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Other Trials (12)

68ga-exendin (1 trial)

bergamot oil (1 trial)

cocoa bean (1 trial)

coffee (2 trials)

dalteparin (fragmin) (1 trial)

glucose (4 trials)

inulin (1 trial)

oryza sativa (1 trial)

polyphenols (1 trial)

tea (1 trial)

vitamin d3 (1 trial)

vitis vinifera (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 3)

Cataract (Phase 3)

Churg-Strauss Syndrome (Phase 2)

Cognition Disorders (Phase 3)

Cognitive Dysfunction (Phase 3)

Coronavirus Infections (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Fibrosis (Phase 3)

Forearm Injuries (Phase 4)

Glaucoma (Phase 4)

Granulomatosis with Polyangiitis (Phase 2)

Heart Failure (Phase 4)

Hypertension (Phase 4)

Hypotension (Phase 4)

Lung Neoplasms (Phase 3)

Microscopic Polyangiitis (Phase 2)

Nausea (Phase 4)

Ocular Hypertension (Phase 4)

Pain, Postoperative (Phase 4)

Pneumonia (Phase 3)

Pneumonia, Viral (Phase 2)

Polyarteritis Nodosa (Phase 2)

Postoperative Nausea and Vomiting (Phase 4)

Retroperitoneal Fibrosis (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

Vasculitis (Phase 2)

Virus Diseases (Phase 2)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 41
  • # of Trial APIs: 62